[go: up one dir, main page]

AR112217A1 - A COMBINATION OF AN INHIBITOR OF MPS1 AND A COMPOUND TAXAN, USES AND PHARMACEUTICAL COMPOSITIONS OF THE latter - Google Patents

A COMBINATION OF AN INHIBITOR OF MPS1 AND A COMPOUND TAXAN, USES AND PHARMACEUTICAL COMPOSITIONS OF THE latter

Info

Publication number
AR112217A1
AR112217A1 ARP180101809A AR112217A1 AR 112217 A1 AR112217 A1 AR 112217A1 AR P180101809 A ARP180101809 A AR P180101809A AR 112217 A1 AR112217 A1 AR 112217A1
Authority
AR
Argentina
Prior art keywords
combination
mps1
inhibitor
compound
taxan
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Riccardo Colombo
Michael Burbridge
Hlne Lelievre
Marie Schoumacher
Zakia Felloussi
Frdrique Cantero
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of AR112217A1 publication Critical patent/AR112217A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una combinación que comprende un inhibidor de MPS1 de fórmula (1) o una de sus sales de adición con un ácido o base farmacéuticamente aceptable, y un compuesto taxano, y composiciones y usos de esta.A combination comprising an MPS1 inhibitor of formula (1) or an addition salts thereof with a pharmaceutically acceptable acid or base, and a taxane compound, and compositions and uses thereof.

ARP180101809 2017-06-30 2018-06-29 A COMBINATION OF AN INHIBITOR OF MPS1 AND A COMPOUND TAXAN, USES AND PHARMACEUTICAL COMPOSITIONS OF THE latter AR112217A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17305847 2017-06-30

Publications (1)

Publication Number Publication Date
AR112217A1 true AR112217A1 (en) 2019-10-02

Family

ID=59313173

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180101809 AR112217A1 (en) 2017-06-30 2018-06-29 A COMBINATION OF AN INHIBITOR OF MPS1 AND A COMPOUND TAXAN, USES AND PHARMACEUTICAL COMPOSITIONS OF THE latter

Country Status (2)

Country Link
AR (1) AR112217A1 (en)
WO (1) WO2019002542A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022414970A1 (en) * 2021-12-15 2024-06-27 Sillajen, Inc. Pharmaceutical compositions comprising modified beta-cyclodextrins
KR20240107189A (en) * 2021-12-15 2024-07-08 신라젠(주) Pharmaceutical combinations for use in the treatment of neoplastic diseases
CA3241111A1 (en) * 2021-12-15 2023-06-22 Heidi Lane Methods of treating neoplastic diseases
MX2024010802A (en) * 2022-03-04 2024-09-11 Sillajen Inc Pharmaceutical combinations for use in the treatment of neoplastic diseases.
EP4506015A1 (en) 2023-08-09 2025-02-12 Nerviano Medical Sciences S.r.l. Combination of a mps1 inhibitor and an antibody drug conjugate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2303891T1 (en) * 2008-06-26 2016-06-30 Les Laboratoires Servier Pyrazolo-quinazolines as protein kinase activity modulators
TW201437211A (en) * 2013-03-01 2014-10-01 Bayer Pharma AG Substituted imidazolium

Also Published As

Publication number Publication date
WO2019002542A1 (en) 2019-01-03

Similar Documents

Publication Publication Date Title
JOP20220008A1 (en) Parp1 inhibitors
CL2018002410A1 (en) Mcl-1 inhibitors and methods of use thereof
MX2022002976A (en) SELECTIVE JAK1 INHIBITORS.
MX2020005063A (en) KRAS G12C INHIBITORS.
AR112217A1 (en) A COMBINATION OF AN INHIBITOR OF MPS1 AND A COMPOUND TAXAN, USES AND PHARMACEUTICAL COMPOSITIONS OF THE latter
UY36151A (en) ? A PHARMACEUTICAL COMPOSITION THAT INCLUDES A 3-QUINASA DELTA PHOSFOINOSYTIDE INHIBITOR AND A CORTICOSTEROID ?.
MX392213B (en) PHARMACEUTICAL COMPOSITIONS COMPRISING GLYCOPYRROLATE SALTS AND 1,1-DIFLUOROETHANE.
CY1126067T1 (en) FUSIONED PYROLINES THAT ACT AS UBIQUITIN-SPECIFIC PROTEASE 30 (USP30) INHIBITORS
CL2019001337A1 (en) Pharmaceutical formulations.
AR107864A1 (en) ACID 7a, 11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO AND PHARMACEUTICAL COMPOSITIONS
AR102981A1 (en) INHIBITORS OF CELL NECROSIS AND METHODS OF PREPARATION OF THE SAME
MX391414B (en) NOVEL BIPHENYL COMPOUND OR SALT THEREOF.
UY37342A (en) COMBINATION OF A BCL-2 INHIBITOR AND AN MCL1 INHIBITOR, USES AND PHARMACEUTICAL COMPOSITIONS OF THESE
MX2019008302A (en) HISTONE DESACETILASE BICYCLE INHIBITORS A.
UY37560A (en) COMBINATION OF AN MCL-1 INHIBITOR AND A TAXAN COMPOUND, USES AND PHARMACEUTICAL COMPOSITIONS OF THIS
MX2017014880A (en) Pharmaceutical compositions and use thereof.
DOP2019000015A (en) COMBINATION OF A BCL-2 INHIBITOR AND AN MCL1 INHIBITOR, USES AND PHARMACEUTICAL COMPOSITIONS OF THESE
CL2019001859A1 (en) Combination of an mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof.
AR106958A1 (en) USEFUL TETRAHYDROTRIAZOLOPIRIMIDINE DERIVATIVES AS HNE INHIBITORS
AR107163A1 (en) QUINASE INHIBITORS
EP4419501A4 (en) CYRTALLAL INFORMATION OF THE RIP1 INHIBITOR
CL2019001046A1 (en) Combination therapy that includes an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer. (divisional application 201601131)
AR113817A1 (en) COMPOUNDS USEFUL TO INHIBIT CDK7
EA201991623A1 (en) COMBINATION MCL-1 INHIBITOR AND TAXANIC COMPOUND, THEIR APPLICATION AND PHARMACEUTICAL COMPOSITIONS
CR20190240A (en) PHARMACEUTICAL FORMULATIONS

Legal Events

Date Code Title Description
FB Suspension of granting procedure